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Abstract
Objectives: Stage III non-small cell lung cancer (NSCLC) has 
a poor prognosis. Reports suggest that five-year survival after 
current treatment is between 14 to 24 percent. The purpose of this 
retrospective study was to investigate the morbidity and mortality 
of patients diagnosed with stage III NSCLC and treated with 
pneumonectomy at the University of Kentucky Medical Center in 
Lexington, KY.
Methods: We reviewed the medical record and tumor registry 
follow-up data on 100 consecutive patients who underwent 
pneumonectomy for lung cancer at the University of Kentucky.
Results: We identified thirty-six patients in stage III who 
underwent pneumonectomy. Ten patients had surgery only, eight 
patients received adjuvant chemotherapy, and eighteen patients 
received neoadjuvant therapy. There was one surgical death in this 
series. Mean follow-up was 2.9 years. One-, three-, and five-year 
survival was 66%, 38%, and 38%, respectively. Five-year survival for 
the group with adjuvant therapy was 60%.
Conclusion: Most lung cancer patients present with advanced 
disease and the prognosis remains poor. Our experience indicates 
resection offers an above average chance of long-term survival when 
supplemented with neoadjuvant and/or adjuvant therapy.
Keywords: Pneumonectomy; non-small cell lung cancer; resection; 
lobectomy; surgery; chemotherapy; neoadjuvant therapy; survival
Introduction
Lung cancer is the leading cause of cancer deaths among men 
and women in the United States with an estimated 156,940 deaths 
attributed to the disease in 2011.1 Pneumonectomy is the surgical 
removal of an entire lung and is one of the surgical treatment 
options available for lung cancer, along with lobectomy and wedge 
resection. The majority of lung cancer resections involve lobectomy, 
with pneumonectomy being a relatively uncommon procedure 
representing less than 15% of all lung cancer resections.2 Along 
with surgery, radiation and chemotherapy also play a vital role in 
the treatment of lung cancer. For patients diagnosed with non-small 
cell lung cancer (NSCLC), the treatment involves a combination 
of surgery, chemotherapy, and radiation. However, for patients 
diagnosed with small cell lung cancer, surgery is not part of the 
treatment regimen.
The purpose of this retrospective study was to investigate 
the morbidity and mortality of patients diagnosed with stage III 
NSCLC and treated with pneumonectomy at the University of 
Kentucky Medical Center in Lexington, KY.
Methods
Between September 1998 and September 2009, one hundred 
patients underwent pneumonectomy for primary lung cancer at the 
University of Kentucky Medical Center in Lexington, Kentucky. The 
data for the study were obtained by analyzing the patient records, 
which included electronic records as well as paper charts. This 
study was reviewed and approved by the University of Kentucky 
Institutional Review Board (approval #08-0529-P2H). Patient 
consent was deemed unnecessary due to patient’s non-identifying 
data collected for study. The demographic data collected included 
age, sex, histological type, and pathologic stage of lung cancer, 
pneumonectomy site, and adjuvant and/or neoadjuvant therapy 
status (Table 1). Additionally, the postoperative complications and 
operative mortality data were obtained from the operative reports 
and hospital stay records. The postoperative complications included 
all complications during the postoperative hospital stay, while the 
postoperative mortality included any mortality occurring within 30 
days post-pneumonectomy or any mortalities occurring during the 
same hospitalization. Long-term follow-up and survival data were 
obtained using the Kentucky Cancer Registry. Mediastinoscopy 
was used to stage the patients in this study. We utilized American 
Joint Committee on Cancer (AJCC) seventh edition TNM staging 
criteria in this study. Additionally, we defined overall survival as the 
percentage of subjects that survived at the end of a defined period, 
which in our case was 1 year, 3 year or 5 years.
Five-year survival was analyzed using the Kaplan-Meier method. 
Survival was compared across the side of resection and the level of 
therapy received (adjuvant and/or neo-adjuvant therapy) using log-
rank tests. Statistical significance was set at p < .05. SPSS™ version 
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19 statistical software was used for all analyses (IBM Corp., New 
York, NY).
A total of one hundred patients were evaluated for this study 
from which thirty-six patients were identified with stage III disease. 
Of the total 36 subjects in this study, 5 subjects had N2 disease 
(14%). Median age of the patients was 61 years with a range of 30-
79 years. There were twenty-three male and thirteen female patients. 
Twenty patients underwent left pneumonectomy (56%), and 
sixteen patients underwent right pneumonectomy. Squamous cell 
carcinoma was identified in twenty-three patients, adenocarcinoma 
in five patients, undifferentiated non-small cell carcinoma in seven 
patients, and mixed (adenosquamous) in one patient. Eighteen 
patients received neoadjuvant chemotherapy and/or radiation, with 
four of these patients eventually receiving additional therapy after 
pneumonectomy; eight patients received adjuvant chemotherapy 
and/or radiation, and ten patients received surgery alone (Table 1).
Table 1: Clinical characteristics of patients with stage III cancer; 
n=36
Clinical characteristic No.
Median age (range), yr 61 (30-79)
Sex
Male 23
Female 13
Primary Site
Left lung 20
Right lung 16
Histologic properties
Squamos cell 23
Adenocarcinoma 5
Non-small cell (undifferentiated) 7
Mixed (adenosquamous) 1
Stage
IIIA 31
IIIB 5
Neoadjuvant therapy 18
Chemotherapy 2
Radiation 0
Chemoradiation 12
Adjuvant therapy 8
Chemotherapy 1
Radiation 1
Chemoradiation 6
Surgery Alone 10
Results
Major postoperative complications occurred in 16 patients, resulting 
in a complication rate of 44%. The most common complication 
was atrial fibrillation occurring in six patients, with urinary tract 
infection being the second most common and occurring in three 
patients (Table 2). There was one postoperative death, resulting 
in a 3% postoperative mortality rate. The cause of death was acute 
myocardial infarct. There were no intraoperative deaths.
Mean follow-up was 2.9 years. Median survival was 23.9 
months (95% C. I. 10.1-37.8 months). Overall, one-, three-, and 
five-year survival was 66%, 38%, and 38%, respectively (Figure 1). 
Five-year survival for the group with adjuvant therapy was 60% 
compared to 33% for the group that received neoadjuvant therapy, 
and 30% for the group that received surgery only (Figure 2). The 
one-, three-, and five-year survival for patients who underwent right 
pneumonectomy was 56%, 29%, and 29%, respectively, compared 
to 74%, 45%, and 45% for left pneumonectomy. The difference in 
survival between left and right pneumonectomy is not statistically 
significant (p-value = 0.343).
Table 2: Postoperative complications in patients with stage III 
NSCLC.
Complicationsa Number of patients (n=36)
Atrial Fibrillation 6
UTI 3
Bronchopleural fistula 2
Pneumonia 1
Supraventricular Tachycardia 1
Chylothorax 1
Other 4
a Includes patients with more than one complication
Figure 1: Survival function after pneumonectomy in stage III non-
small cell lung cancer. Stage 3 patients, n=36. 1y survival = 66%, 3y 
survival = 38%, and 5y survival = 38%.
Figure 2: Survival function after pneumonectomy in stage III non-
small cell lung cancer by level of adjuvant therapy.
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Discussion
The overall 1-, 3-, and 5-year survival for patients in this report 
compares favorably to the data in recently published literature. In 
the study by Ferguson, et al. the overall 1-, 3-, and 5-year survival 
was 52%, 28%, and 21%, respectively, for stage III NSCLC, while 
Friedel et al. noted 5-year overall survival of 22%.3,4 Stamatis et 
al. report 5-year overall survival of 36% for stage IIIA disease and 
26% for stage IIIB disease.5 Additionally, Decaluwe et al. report a 
5-year survival of 33%.6 Results published in recent literature are 
comparable to the results we observed in our study, with favorable 
5-year overall survival of 38% for stage III NSCLC.
Many studies have tried to understand the role of neoadjuvant 
therapy in the treatment of patients diagnosed with NSCLC. The 
30-day postoperative mortality for our neoadjuvant group was 5.6% 
with 1 death out of 18 patients. The literature shows mixed results 
with some publications indicating that neoadjuvant therapy results 
in a significant increase in postoperative mortality. A study published 
by Albain et al. showed a high postoperative mortality rate of 26% 
(14/54) for stage III NSCLC patients who received neoadjuvant 
chemoradiation.7 Daly et al. report a postoperative mortality rate 
of 13.3% (4/30) and concluded that neoadjuvant chemoradiation 
therapy is associated with high mortality but results in significant 
long-term survival for patients who survive with a 5-year survival rate 
of 38%.8 Similarly, Venuta et al. observed a mortality rate of 12.5% 
(4/32) for patients who received neoadjuvant therapy and concluded 
that pneumonectomy should only be performed in carefully selected 
patients.9 However, Alan et al. report a low postoperative mortality 
rate of 5.6% and conclude that there is no significant increase in 
postoperative mortality after pneumonectomy in those who received 
neoadjuvant chemotherapy.10 Similarly, Ng et al. did not observe any 
significant difference in postoperative mortality between the group 
that underwent neoadjuvant therapy (with no mortalities out of 17 
patients) and the group that did not receive neoadjuvant therapy.11
In our study, the postoperative mortality of 5.6% for patients with 
stage III disease undergoing neoadjuvant therapy was relatively low, 
and there was not a significant increase when compared to the overall 
mortality rate of 3%. With the results we obtained at our institution, 
we can conclude that induction therapy can be safely performed for 
patients with stage III disease undergoing pneumonectomy.
For patients who underwent neoadjuvant therapy, the 1-, 3-, 
and 5-year survival was 60%, 33%, and 33%. For patients who 
only received surgical intervention, the 1-, 3, and 5-year survival 
was 56%, 30%, and 30%. The long-term survival between these 
two groups was comparable and the differences are not statistically 
significant. Weder et al. report 3-year survival of 43% and 5-year 
survival of 38%.12 Allen et al. report similar survival rates with 1-, 
3-, 5-year survival of 70%, 49%, and 20%, respectively, for patients 
with stage III disease who underwent neoadjuvant chemoradiation 
followed by pneumonectomy.13 Similarly, Paul et al. report 5-year 
survival of 22% for patients with stage IIIA disease who underwent 
induction therapy prior to pneumonectomy.14 Additionally, a phase 
III randomized control trial by Albain et al. showed 5-year survival 
of 25% for patients who received radiotherapy plus chemotherapy 
prior to undergoing pneumonectomy.15 The 5-year survival of 33% 
that we observed at our institution is comparable to the results 
published in recent literature and allows us to conclude that 
neoadjuvant therapy is a valuable option for treatment of patients 
diagnosed with stage III NSCLC as it converts many non-resectable 
tumors to a resectable stage and offers long-term survival benefits. 
Neoadjuvant therapy should be considered as part of overall therapy 
for stage III NSCLC.
In our study, a 5-year survival of 60% for the adjuvant therapy 
group was significantly higher than the group that received 
neoadjuvant therapy and was also higher than the group that 
received surgery alone, 33% and 30%, respectively. The International 
Adjuvant Lung Cancer Trial from 2004 looked at the role of 
adjuvant chemotherapy. The study divided patients with stage IB 
to IIIA disease (39% of patients had stage IIIA disease) into two 
groups, with one group receiving adjuvant chemotherapy and the 
other group receiving surgery alone. In addition, patients with stage 
IIIA disease also received adjuvant radiation therapy regardless of 
which group they were assigned to. The adjuvant chemotherapy 
group showed improved survival (5-year survival of 44.5% versus 
40% for control group, p < 0.03) with stage IIIA patients showing 
the greatest benefit. Additionally, the disease-free survival was 
significantly higher in the chemotherapy group (5-year survival of 
39.4% vs. 34.3%, p < 0.003.)16 In addition, a recently published study 
by Douillard et al. showed significantly improved 5-year survival 
(42% versus 26%, p=0.013) for stage IIIA patients who received 
adjuvant chemotherapy.17 With these results, the American College 
of Chest Physicians (ACCP) Evidence-Based Clinical Practice 
Guidelines (2nd Edition) gave a 1A recommendation to the use of 
adjuvant chemotherapy in patients found to have incidental IIIA 
N2 disease. The ACCP recommendation for adjuvant radiotherapy 
is 2C, with the comment that adjuvant radiotherapy should be 
considered after adjuvant chemotherapy to reduce local recurrence.18
Because the most important factor that results in reduced survival 
in patients with lung cancer is systemic recurrence, adjuvant therapy, 
especially chemotherapy, may play an important role in improving 
the long-term survival by reducing systemic spread.
Conclusions
In our study, a 60% 5-year survival rate for the adjuvant therapy 
group demonstrates the benefit of adjuvant therapy in increasing 
the long-term survival in patients with stage III disease. Results 
from our study provide further evidence for a definitive role of 
adjuvant therapy in treatment of stage III disease to improve long-
term survival.
In summary, for patients diagnosed with stage III NSCLC, 
multimodality therapy may offer the best survival benefits. 
Neoadjuvant therapy prior to pneumonectomy converts many non-
resectable tumors to a resectable stage and subsequently offers long-
term survival benefits, and in our experience, it did not significantly 
increase the postoperative mortality. Adjuvant therapy may 
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significantly improve long-term survival and should be considered 
an important part of treatment for patients diagnosed with stage 
III NSCLC. Most lung cancer patients present with advanced 
disease and the prognosis remains poor. In the surgeon’s hands, 
resection offers an above average chance of long-term survival when 
supplemented with neoadjuvant and/or adjuvant therapy.
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